Micromedic unit wins CE approval

A second unit received positive results from a throat cancer study

Micromedic Technologies Ltd. (TASE:MCTC) unit Microvascular Eye Technology Ltd. (MET), has received EU CE Mark certification for its treatment for varicose veins. MET is a Micromedic investment from the period when it sought to be a general healthcare holdings company, rather than focusing on biomarkers for cancer. The company has developed"SpiderCan", a miniature syringe that can be used on small blood vessels. It abandoned its first product for the eyes, after realizing the market was not lucrative enough, but applied the technology to another product for the treatment of varicose veins. A CE Mark Certification asserts that a product is safe to use and meets quality standards, but does not assess its efficacy.

In a separate development, another Micromedic unit, Bio Med Technologies Ltd., successfully completed preliminary clinical trials of its marker for the diagnosis of cancer of the head and neck. This is one of Micromedic's projects focusing on cancer, which was founded on the basis of technology licensed to the company by the University of Florida. The company found that the university's marker for the diagnosis of head and neck cancer detected the disease in all of the 25 patients tested, and did not detect cancer in any of the 10 healthy subjects who also took part in the trial.

Published by Globes [online], Israel business news - www.globes-online.com - on April 30, 2008

© Copyright of Globes Publisher Itonut (1983) Ltd. 2008

View comments in rows
Update by email about comments talkback
Your name
Please insert your name
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Twitter Facebook Linkedin RSS Newsletters גלובס Capital  Markets Conference 2017